• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Histogen Announces Board Approval of Complete Liquidation and Dissolution

    9/18/23 4:05:04 PM ET
    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HSTO alert in real time by email

    SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September.

    "The Board of Directors and management devoted substantial time and effort in identifying and pursuing various opportunities, but we were unable to complete a transaction that would allow us the potential to enhance stockholder value," stated Steven J. Mento, Ph.D., President and Chief Executive Officer of Histogen.

    Evaluation of Strategic Options

    As previously reported, Histogen commenced a process to explore strategic alternatives by engaging Roth Capital Partners, LLC, to act as a strategic advisor in the process. To date, no viable strategic alternatives are available to the company. However, the company continues to explore certain strategic options that may be available for the potential sale of any of its pipeline assets. In the event that the company is successful in selling any assets of the company, the proceeds from any such sale would be distributed to stockholders in accordance with the Plan of Dissolution. The amount that would actually be available for distribution to stockholders, if any, is dependent on a number of factors.

    Workforce Reduction Including Officers

    In order to reduce costs and in connection with the planned dissolution, Histogen has reduced its workforce, including the termination of all employees except for two remaining employees, effective as of September 30, 2023. This includes the termination of employment of all officers except for Susan Knudson, who effective as of October 1, 2023 will serve in addition to her role as Chief Financial Officer, Secretary and principal financial officer, as the company's President, Chief Executive Officer and principal executive officer. Steven J. Mento, Ph.D., the company's President, Chief Executive Officer and principal executive officer, Alfred P. Spada, Ph.D., the Company's Executive Vice President and Chief Scientific Officer, and Joyce Reyes, the Company's Senior Vice President Regulatory, Quality, Clinical and Technical Operations, were all terminated from all positions of employment with the company, effective as of September 30, 2023. Dr. Mento resigned as a director from the Histogen board of directors effective as of September 18, 2023.

    Board Approval of Plan of Dissolution

    On September 18, 2023, Histogen's board of directors approved the liquidation and dissolution of the company pursuant to the Plan of Dissolution, subject to stockholder approval. The company intends to call a special meeting of its stockholders in the fourth quarter of 2023 to seek approval of the Plan of Dissolution and will file proxy materials with the Securities and Exchange Commission ("SEC") as soon as practicable.

    The Plan of Dissolution contemplates an orderly wind down of Histogen's business and operations. If Histogen's stockholders approve the Plan of Dissolution, Histogen intends to file a certificate of dissolution, delist its shares of common stock from The Nasdaq Capital Market, satisfy or resolve its remaining liabilities and obligations, including but not limited to contingent liabilities and claims and costs associated with the dissolution, make reasonable provisions for unknown claims and liabilities, attempt to convert all of its remaining assets into cash, and make distributions to its stockholders of any remaining cash available for distribution based upon their proportionate ownership at the time of the filing of the certificate of dissolution, subject to applicable legal requirements. Upon the filing of the certificate of dissolution, Histogen intends to cease trading in its common stock, close its stock transfer books and discontinue recording transfers of shares of its capital stock, in accordance with applicable law. Histogen currently expects that its existing capital resources together with the anticipated net proceeds from any sale of pipeline assets will enable it to meet its remaining liabilities and obligations with sufficient reserves. The amount actually distributable, however, may vary substantially from any estimate provided by the company based on a number of factors.

    IMPORTANT ADDITIONAL INFORMATION

    In connection with the proposed Plan of Dissolution, the Company intends to file with the SEC a proxy statement and other relevant materials. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PLAN OF DISSOLUTION AND RELATED MATTERS OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT HISTOGEN INC., THE PLAN OF DISSOLUTION AND RELATED MATTERS. Shareholders may obtain a free copy of the proxy statement and the other relevant materials (when they become available), and any other documents filed by the Company with the SEC, at the SEC's website at http://www.sec.gov or on the "Investors" section of Histogen's website at www.histogen.com.

    Participants in the Solicitation

    Histogen and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the Plan. Information about the persons who may be considered to be participants in the solicitation of the Company's stockholders in connection with the Plan, and any interest they have in the Plan, will be set forth in the definitive proxy statement when it is filed with the SEC. These documents (when they become available) may be obtained free of charge at the SEC's website at www.sec.gov or on the "Investors" section of Histogen's website at www.histogen.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements.

    For example, all statements Histogen makes regarding the proposed dissolution pursuant to the Plan of Dissolution, timing of filing of the certificate of dissolution and holding a special stockholder meeting to approve the Plan of Dissolution, the amount and timing of liquidating distributions, if any, in connection with the dissolution, the amount of planned reserves, and similar statements are forward-looking. All forward-looking statements are based on estimates and assumptions by Histogen's management that, although Histogen believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Histogen expected. Such risks and uncertainties include, among others, the availability, timing and amount of liquidating distributions; the amounts that will need to be set aside by Histogen; the adequacy of such reserves to satisfy Histogen's obligations; potential unknown contingencies or liabilities, including tax claims, and Histogen's ability to favorably resolve them or at all; the amount of proceeds that might be realized from the sale or other disposition of any remaining assets; the application of, and any changes in, applicable tax laws, regulations, administrative practices, principles and interpretations; the incurrence by Histogen of expenses relating to the dissolution; the ability to achieve shareholder approval of the Plan of Dissolution; the ability of the board of directors to abandon, modify or delay implementation of the Plan of Dissolution, even after shareholder approval; and the uncertain macroeconomic environment. Any forward-looking statement speaks only as of the date on which it was made. Histogen undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

    CONTACT:

    Susan A. Knudson

    Executive Vice President, COO & CFO

    Histogen Inc.

    [email protected] 



    Primary Logo

    Get the next $HSTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSTO

    DatePrice TargetRatingAnalyst
    8/30/2021$2.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $HSTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Histogen Announces Second Adjournment of Special Meeting of Stockholders

      Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v

      12/14/23 4:15:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Adjournment of Special Meeting of Stockholders

      SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob

      12/5/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Board Approval of Complete Liquidation and Dissolution

      SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem

      9/18/23 4:05:04 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Histogen Inc.

      15-12G - Histogen Inc. (0001383701) (Filer)

      1/4/24 1:21:25 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Histogen Inc.

      DEFA14A - Histogen Inc. (0001383701) (Filer)

      12/15/23 4:05:05 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Histogen Inc.

      425 - Histogen Inc. (0001383701) (Subject)

      12/14/23 4:25:01 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

      SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team.  Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief E

      1/3/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

      Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

      8/8/22 8:45:00 AM ET
      $CVM
      $HSTO
      $TXMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Orhub's Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts

      A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr

      7/27/22 2:30:00 PM ET
      $BAX
      $HSTO
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $HSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/14/23 12:56:27 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/8/23 6:07:04 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/11/22 7:06:22 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Windham-Bannister Susan Richards

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:11:05 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Satz Brian

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:10:02 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kisner Daniel L

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:09:19 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Histogen with a new price target

      HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40

      8/30/21 6:17:04 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Histogen with a new price target

      Canaccord Genuity reiterated coverage of Histogen with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      6/4/21 10:01:35 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Histogen with a new price target

      Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00

      3/10/21 8:10:32 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Financials

    Live finance-specific insights

    See more
    • Histogen Reports Year-End 2022 Results and Provides Business Update

      SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res

      3/9/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus ("MRSA") and evaluating our caspase-1 inh

      11/10/22 4:15:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

      Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We continue to focus on execution of IND enabling activities for HST 004 in spinal disc regeneration, exploration of testing emricasan in ani

      8/11/22 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care